These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 10371490)

  • 1. HIV-1 and HAART: a time to cure, a time to kill.
    Saag MS; Kilby JM
    Nat Med; 1999 Jun; 5(6):609-11. PubMed ID: 10371490
    [No Abstract]   [Full Text] [Related]  

  • 2. Latent reservoirs of HIV infection: flushing with IL-2?
    Cooper DA; Emery S
    Nat Med; 1999 Jun; 5(6):611-2. PubMed ID: 10371491
    [No Abstract]   [Full Text] [Related]  

  • 3. IL-2 taken to HAART.
    Gilden D
    GMHC Treat Issues; 1999 Feb; 13(2):4-6. PubMed ID: 11366116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ongoing HIV dissemination during HAART.
    Grossman Z; Polis M; Feinberg MB; Grossman Z; Levi I; Jankelevich S; Yarchoan R; Boon J; de Wolf F; Lange JM; Goudsmit J; Dimitrov DS; Paul WE
    Nat Med; 1999 Oct; 5(10):1099-104. PubMed ID: 10502799
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy.
    Chun TW; Engel D; Mizell SB; Hallahan CW; Fischette M; Park S; Davey RT; Dybul M; Kovacs JA; Metcalf JA; Mican JM; Berrey MM; Corey L; Lane HC; Fauci AS
    Nat Med; 1999 Jun; 5(6):651-5. PubMed ID: 10371503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Viral dynamics in the course of HIV-1 infection: pathogenetic features and new therapeutic prospects].
    Marcello A; Giacca M
    Pathologica; 2000 Aug; 92(4):291-3. PubMed ID: 11029891
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of antiretroviral therapy on plasma HIV RNA.
    Saag MS
    J Biol Regul Homeost Agents; 1995; 9(3):105-6. PubMed ID: 8782017
    [No Abstract]   [Full Text] [Related]  

  • 8. Discordant immunological and virological responses to antiretroviral therapy.
    Schechter M; Tuboi SH
    J Antimicrob Chemother; 2006 Sep; 58(3):506-10. PubMed ID: 16854959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discordant movement of CD4-positive T-cell count in HIV-1 infected patients with HAART failure.
    Okano A; Matsuda M; Chiba T; Moriya K; Yamada K; Sugiura W
    Jpn J Infect Dis; 2002 Apr; 55(2):62-5. PubMed ID: 12082315
    [No Abstract]   [Full Text] [Related]  

  • 10. Therapeutic options or antiretroviral anarchy?
    Mascolini M
    J Int Assoc Physicians AIDS Care; 1999 Jan; 5(1):10-30. PubMed ID: 11366158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms underlying activity of antiretroviral drugs in HIV-1-infected macrophages: new therapeutic strategies.
    Aquaro S; Svicher V; Schols D; Pollicita M; Antinori A; Balzarini J; Perno CF
    J Leukoc Biol; 2006 Nov; 80(5):1103-10. PubMed ID: 16931601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro induction of HIV-1 replication in resting CD4(+) T cells derived from individuals with undetectable plasma viremia upon stimulation with human T-cell leukemia virus type I.
    Moriuchi H; Moriuchi M
    Virology; 2000 Dec; 278(2):514-9. PubMed ID: 11118373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamics of the pool of infected resting CD4 HLA-DR- T lymphocytes in patients who started a triple class five-drug antiretroviral regimen during primary HIV-1 infection.
    Sankatsing SU; van Praag RM; van Rij RP; Rientsma R; Jurriaans S; Lange JM; Prins JM; Schuitemaker H
    Antivir Ther; 2003 Apr; 8(2):137-42. PubMed ID: 12741626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Residual HIV-1 disease in the era of highly active antiretroviral therapy.
    Pomerantz RJ
    N Engl J Med; 1999 May; 340(21):1672-4. PubMed ID: 10341281
    [No Abstract]   [Full Text] [Related]  

  • 15. Decrease of replicative capacity of HIV isolates after genotypic guided change of therapy.
    Sarmati L; Nicastri E; Montano M; Dori L; Buonomini AR; d'Ettorre G; Gatti F; Parisi SG; Vullo V; Andreoni M
    J Med Virol; 2004 Apr; 72(4):511-6. PubMed ID: 14981751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Failure to reconstitute CD4+ T-cells despite suppression of HIV replication under HAART.
    Aiuti F; Mezzaroma I
    AIDS Rev; 2006; 8(2):88-97. PubMed ID: 16848276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiretroviral therapy for HIV-1 vaccine efficacy trial participants who seroconvert.
    Kim HN; Tabet SR; Corey L; Celum CL
    Vaccine; 2006 Jan; 24(4):532-9. PubMed ID: 16242816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
    Li H; Zheng YH; Shen Z; Liu M; Liu C; He Y; Chen J; Ou QY; Huang ZL
    Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(42):2973-6. PubMed ID: 18261327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamics of HIV viral load in blood and semen of patients under HAART: impact of therapy in assisted reproduction procedures.
    La Sala GB; Pilotti E; Nicoli A; Pinelli S; Villani MT; Ronzi P; Zendri E; Re MC; Magnani G; Casoli C
    AIDS; 2007 Jan; 21(3):377-9. PubMed ID: 17255749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamics of proviral HIV-1 184M/V in circulating CD4+ T-cells: a 90 days follow-up study after initiation/switch of HAART.
    Mohey R; Katzenstein TL; Black FT; Kjems J; Obel N
    Scand J Infect Dis; 2006; 38(2):119-23. PubMed ID: 16449003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.